Printer Friendly

Research and Markets: Antidyslipidemics Market and Product Forecasts: Set for the Impact of Generic Lipitor.

DUBLIN -- Research and Markets ( has announced the addition of the "Market and Product Forecasts: Antidyslipidemics - Set for the impact of generic Lipitor" report to their offering.

The industry is bracing itself for the impact of the Lipitor (atorvastatin, Pfizer) patent cliff which is anticipated to cause large shifts in the antidyslipidemic market. Clinical trials continue to produce an evidence base that justifies the dominant position held by statins and struggle to clearly prove the benefit of add-on therapies.

Features and benefits:

* Forecast leading antidyslipidemic brands in the 2010-2020 period

* Quantify the sales potential late-stage pipeline products

* Assess the impact of key patent expiries, such as Pfizer's Lipitor (atorvastatin);

* Determine the impact of recent clinical trial results and ongoing trials


* Crestor and Lipitor stand ahead of the competition by a considerable distance. The two brands generated sales of $13.5 billion together in 2010 across the seven major markets, this equates to 63% of the top 10 antidyslipidemic brands. Statins remain the gold standard first-line therapy for low density lipoprotein cholesterol (LDL-C) management.

* Pipeline antidyslipidemics are positioned as add-on to statins, targeting residual risk by modulating lipid parameters other than LDL-C. The availability of generics of not only statins but Niaspan, Zetia and Tricor will create an environment that will make establishing market share for a premium product more challenging than ever.

* GlaxoSmithKline's prescription formulation of the omega oils eicosapentaenoic acid plus docosahexanoic acid Lovaza has shown strong growth and is positioned to record blockbuster sales in 2011. Pipeline purified omega oil AMR101 (ethyl icosapentate; Amarin) is positioned well to gain market share in this class.

Your key questions answered:

* Use the Datamonitor forecast to quantify the impact of the Lipitor patent cliff by country, molecule and brand

* Identify which brands will grow in the forecast period

* View sales and volume forecasts for pipeline drugs for 2010-2020 and which markets are more receptive to growth

For more information visit
COPYRIGHT 2012 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2012 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 18, 2012
Previous Article:Paul Taylor to Succeed Stephen Joynt as CEO of Fitch Group.
Next Article:Fitch: U.S. MMF Shadow NAV Volatility Declines Post-Crisis.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters